Published in J Immunol on October 15, 2009
The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol (2010) 3.57
Retracted FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest (2011) 2.44
Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol (2010) 2.28
Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol (2010) 1.22
Prostate cancer immunotherapy. Clin Cancer Res (2011) 1.11
Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J Immunol (2012) 1.09
T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol Ther (2013) 1.07
Interleukin 35: a key mediator of suppression and the propagation of infectious tolerance. Front Immunol (2013) 1.03
Retracted High-avidity T cells are preferentially tolerized in the tumor microenvironment. Cancer Res (2012) 1.01
Orchestration of angiogenesis by immune cells. Front Oncol (2014) 0.97
The role of regulatory T cells in cancer. Immune Netw (2009) 0.93
Protective CD8 memory T cell responses to mouse melanoma are generated in the absence of CD4 T cell help. PLoS One (2011) 0.93
Immunotherapy for prostate cancer: biology and therapeutic approaches. J Clin Oncol (2011) 0.91
Retracted Isolation of immune cells from primary tumors. J Vis Exp (2012) 0.90
FOXO3: A master switch for regulating tolerance and immunity in dendritic cells. Oncoimmunology (2012) 0.87
Shaping the repertoire of tumor-infiltrating effector and regulatory T cells. Immunol Rev (2014) 0.85
A combination of local inflammation and central memory T cells potentiates immunotherapy in the skin. J Immunol (2012) 0.85
Human tumor infiltrating lymphocytes cooperatively regulate prostate tumor growth in a humanized mouse model. J Immunother Cancer (2015) 0.80
CD8⁺ Foxp3⁺ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response. Int J Cancer (2010) 0.80
Monitoring regulatory immune responses in tumor immunotherapy clinical trials. Front Oncol (2013) 0.79
Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model. J Vis Exp (2015) 0.79
Bisphenol A Disrupts HNF4α-Regulated Gene Networks Linking to Prostate Preneoplasia and Immune Disruption in Noble Rats. Endocrinology (2015) 0.79
To affinity and beyond: harnessing the T cell receptor for cancer immunotherapy. Hum Vaccin Immunother (2014) 0.78
Extending the lifespan and efficacies of immune cells used in adoptive transfer for cancer immunotherapies-A review. Oncoimmunology (2015) 0.78
Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy. Arch Immunol Ther Exp (Warsz) (2010) 0.78
Challenges and future perspectives of T cell immunotherapy in cancer. Immunol Lett (2015) 0.78
Whole-body irradiation increases the magnitude and persistence of adoptively transferred T cells associated with tumor regression in a mouse model of prostate cancer. Cancer Immunol Res (2014) 0.77
T cell avidity and tumor immunity: problems and solutions. Cancer Microenviron (2013) 0.77
Enhancement of the T-cell armamentarium as a cell-based therapy for prostate cancer. Cancer Res (2014) 0.77
Comparison of adjuvant activity of N- and C-terminal domain of gp96 in a Her2-positive breast cancer model. Cell Stress Chaperones (2011) 0.77
Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus. Nature (2005) 8.55
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity (2008) 5.35
Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis (2009) 4.71
Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate (2003) 3.44
Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res (2007) 3.25
Genomic islands in the pathogenic filamentous fungus Aspergillus fumigatus. PLoS Genet (2008) 3.23
Reduction of information redundancy in the ascending auditory pathway. Neuron (2006) 2.69
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Retracted FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest (2011) 2.44
Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res (2006) 2.39
Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am J Pathol (2009) 2.14
Evidence for sexuality in the opportunistic fungal pathogen Aspergillus fumigatus. Curr Biol (2005) 2.12
Retracted Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells. Cancer Res (2009) 2.00
Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer (2007) 1.94
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci U S A (2005) 1.73
Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol (2004) 1.71
The current state of preclinical prostate cancer animal models. Prostate (2008) 1.68
Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer. J Immunol (2007) 1.67
Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate. Fungal Genet Biol (2002) 1.66
Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. Cancer Res (2005) 1.62
A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease. Int J Cancer (2012) 1.60
IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. J Immunol (2004) 1.46
A cautionary tale: Lack of consistency in allele sizes between two laboratories for a published multilocus microsatellite typing system. J Clin Microbiol (2006) 1.43
Development of regulatory T cells requires IL-7Ralpha stimulation by IL-7 or TSLP. Blood (2008) 1.43
MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res (2011) 1.39
Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res (2005) 1.36
Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations. Cancer Res (2008) 1.36
A new three-dimensional ultrasound microimaging technology for preclinical studies using a transgenic prostate cancer mouse model. Cancer Res (2005) 1.34
Insight into the genome of Aspergillus fumigatus: analysis of a 922 kb region encompassing the nitrate assimilation gene cluster. Fungal Genet Biol (2004) 1.33
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Targeting Aurora kinases for the treatment of prostate cancer. Cancer Res (2006) 1.31
Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur J Immunol (2005) 1.29
The influence of IL-2 family cytokines on activation and function of naturally occurring regulatory T cells. J Leukoc Biol (2008) 1.26
Molecular mechanisms of primary resistance to flucytosine in Candida albicans. Antimicrob Agents Chemother (2004) 1.25
Regulated expression of Wnts and Frizzleds at specific stages of follicular development in the rodent ovary. Endocrinology (2002) 1.24
Conditional deletion of Rb causes early stage prostate cancer. Cancer Res (2004) 1.23
The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J Transl Med (2003) 1.23
Expression of costimulatory TNFR2 induces resistance of CD4+FoxP3- conventional T cells to suppression by CD4+FoxP3+ regulatory T cells. J Immunol (2010) 1.23
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci U S A (2008) 1.22
Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model. Neoplasia (2007) 1.22
Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res (2007) 1.22
Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice. Cancer Res (2007) 1.18
Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. Cancer Res (2003) 1.18
Sequencing the Aspergillus fumigatus genome. Lancet Infect Dis (2002) 1.16
Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res (2003) 1.16
Functional neoangiogenesis imaging of genetically engineered mouse prostate cancer using three-dimensional power Doppler ultrasound. Cancer Res (2007) 1.16
Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay. J Transl Med (2004) 1.15
beta1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts. Cancer Res (2005) 1.14
Role of epithelial cell fibroblast growth factor receptor substrate 2alpha in prostate development, regeneration and tumorigenesis. Development (2008) 1.13
Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer. Prostate (2003) 1.12
Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis. J Clin Invest (2013) 1.10
Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen. Vaccine (2009) 1.09
Amplification in the rehabilitation of unilateral deafness: speech in noise and directional hearing effects with bone-anchored hearing and contralateral routing of signal amplification. Otol Neurotol (2006) 1.08
Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells. J Immunother (2009) 1.08
Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium. Cancer Res (2008) 1.07
Blockade of transforming growth factor-{beta} signaling in tumor-reactive CD8(+) T cells activates the antitumor immune response cycle. Mol Cancer Ther (2006) 1.05
Use of anticholinergic medications by older adults with dementia. J Am Geriatr Soc (2002) 1.05
A novel flow cytometric assay for evaluating cell-mediated cytotoxicity. J Immunother (2005) 1.03
β4 Integrin signaling induces expansion of prostate tumor progenitors. J Clin Invest (2013) 1.03
Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: evidence from the transgenic adenocarcinoma of the mouse prostate system. Cancer Res (2003) 1.02
Retracted High-avidity T cells are preferentially tolerized in the tumor microenvironment. Cancer Res (2012) 1.01
Differential expression of cell cycle regulatory molecules and evidence for a "cyclin switch" during progression of prostate cancer. Prostate (2004) 1.01
Interrogation of related clinical pan-azole-resistant Aspergillus fumigatus strains: G138C, Y431C, and G434C single nucleotide polymorphisms in cyp51A, upregulation of cyp51A, and integration and activation of transposon Atf1 in the cyp51A promoter. Antimicrob Agents Chemother (2011) 0.98
Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model. J Urol (2005) 0.97
The role of ascorbate in the modulation of HIF-1alpha protein and HIF-dependent transcription by chromium(VI) and nickel(II). Free Radic Biol Med (2007) 0.97
Cooperation between ectopic FGFR1 and depression of FGFR2 in induction of prostatic intraepithelial neoplasia in the mouse prostate. Cancer Res (2003) 0.96
Androgens and prostate cancer: are the descriptors valid? Cancer Biol Ther (2005) 0.95
Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression. Prostate (2003) 0.93
Molecular targeted enhanced ultrasound imaging of flk1 reveals diagnosis and prognosis potential in a genetically engineered mouse prostate cancer model. Mol Imaging (2009) 0.92
Dietary genistein improves survival and reduces expression of osteopontin in the prostate of transgenic mice with prostatic adenocarcinoma (TRAMP). J Nutr (2005) 0.92
Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model. Prostate (2007) 0.92
Diagnostic and prognostic sarcoma signatures. Mol Diagn Ther (2008) 0.92
Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype. J Cell Biochem (2004) 0.91
A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. Oncogene (2005) 0.90
Characterization of the oncogenic activity of the novel TRIM59 gene in mouse cancer models. Mol Cancer Ther (2011) 0.90
Retracted Isolation of immune cells from primary tumors. J Vis Exp (2012) 0.90
Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer. Prostate (2008) 0.89
Application of a flow cytometric cytotoxicity assay for monitoring cancer vaccine trials. J Immunother (2009) 0.88
Genomics of Aspergillus fumigatus. Rev Iberoam Micol (2005) 0.88
FOXO3: A master switch for regulating tolerance and immunity in dendritic cells. Oncoimmunology (2012) 0.87
Suppression of tumor metastasis by blockade of transforming growth factor beta signaling in bone marrow cells through a retroviral-mediated gene therapy in mice. Cancer Res (2002) 0.87
Differential regulation of insulin-like growth factor-I receptor gene expression by wild type and mutant androgen receptor in prostate cancer cells. Mol Cell Endocrinol (2010) 0.87
Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands of transgenic mice. Differentiation (2002) 0.86
Application of the granzyme B ELISPOT assay for monitoring cancer vaccine trials. J Immunother (2006) 0.86
Retinoic acid slows progression and promotes apoptosis of spontaneous prostate cancer. Prostate (2004) 0.85
Cell-intrinsic abrogation of TGF-β signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer. J Immunol (2012) 0.85
How many patients complete an adequate trial of donepezil? Alzheimer Dis Assoc Disord (2002) 0.85
Percutaneous venovenous CO2 removal with regional anticoagulation in an ovine model. ASAIO J (2006) 0.85
T cell tolerance to tumors and cancer immunotherapy. Adv Exp Med Biol (2007) 0.85